1 to 2 days, single or multiple exposures
acute toxicity
repeated exposure, less than 3 months
subacute toxicity
repeated exposure, greater than 3 months
chronic toxicity
-measures toxic response on an individual to various doses, response for each toxxic effect or molecular interaction will be different
individual/graded dose response
-measures responses in a population of individuals as dose increases
quantal response
LD50/ED50 (animals) or toxic dose over therapeutic dose in humans
therapeutic index
LD1/ED99 or TD/ED99 for humans
margin of safety
the probability that injury will result from exposure to a substance under specified conditions of dose and route of administration
risk
expression of adverse effects, more clinically useful than therapeutic index
benefit to risk ratio
hormesis
toxicity
fetal toxicity
-abnormal response resulting from previous sensitizing exposure activating immunologic mechanism
drug allergy (hypersensitivity)
drug allergies (hypersensitivity)
type 1 anaphylactic rxn
type 2 cytotoxic (autoimmune) hypersensitivity
type 3 immune complex rxn
- often caused by genetic abnormalities in enzymes or receptors (pharmacogenomics)
drug idiosyncracies
idiosyncracies: patents with abnormal ________ develop apnea when given normal doses of succinylcholine
serum cholinesterase
slow acetylators of isoniazid have low hepatic ______ activity, more prone to B6 deficiency
N-acetyltransferase
hemolytic anemia elicited by _______ in patients whose red cells are deficient in G6PDH, affects about 10% of black men
primaquine
barbiturate induce __________ occurs in individuals with abnormal heme biosynthesis, mimics part of heme structure occupying portion of protein that regulates ALA synthetase, inhibits production
barbiturate
paraquat
-binds heme iron in cytochrome A3 of complex 4, blocks ATP formation
cyanide poisoning